论文部分内容阅读
目的:探讨环氧化-酶2(COX-2)、表皮生长因子受体(EGFR)在胸腺瘤组织中表达的生物学意义及其相互关系。方法:采用免疫组织化学SP法,检测53例胸腺瘤患者中COX-2、EGFR的表达,用5例正常胸腺组织作对照。结果:53例胸腺瘤组织中,随着Masaoka分期进展,COX-2、EGFR阳性表达率逐渐升高,差异有统计学意义,χ2值分别为7.283和5.330,P值分别为0.007和0.021。COX-2和EGFR的阳性表达率与胸腺瘤的Masaoka分期及淋巴结转移等参数有关,P<0.05;与胸腺瘤组织学分型无关,P>0.05。COX-2与EGFR的表达呈正相关,r=0.811,P<0.01。结论:胸腺瘤的浸润性发展与COX-2及EGFR的增强表达具有相关性,COX-2及EGFR在肿瘤细胞的增强表达可作为胸腺瘤恶性度和判断预后的重要生物学指标,并可为临床医生提供诊断和辅助治疗依据。
Objective: To investigate the biological significance of COX-2 and epidermal growth factor receptor (EGFR) expression in thymoma and their relationship. Methods: Immunohistochemical SP method was used to detect the expression of COX-2 and EGFR in 53 cases of thymoma, and 5 cases of normal thymus were used as control. Results: In 53 cases of thymoma, the positive rates of COX-2 and EGFR increased with the Masaoka stage, the difference was statistically significant (χ2 = 7.283 and 5.330, P = 0.007 and 0.021, respectively). The positive rates of COX-2 and EGFR were related to Masaoka stage and lymph node metastasis of thymoma (P <0.05), but not to the histological type of thymoma (P> 0.05). The expression of COX-2 and EGFR was positively correlated, r = 0.811, P <0.01. CONCLUSIONS: The invasiveness of thymoma is correlated with the enhanced expression of COX-2 and EGFR. The enhanced expression of COX-2 and EGFR in tumor cells may be used as an important biological indicator of malignancy and prognosis of thymoma, and may be Clinicians provide the basis for diagnosis and adjuvant therapy.